Evidence map›Paper›PMID 31954639›Full record

ArticleJACC. Cardiovascular imaging2020

Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.

Pratik S Velangi, Ko-Hsuan Amy Chen, Felipe Kazmirczak, Osama Okasha, Lisa von Wald, Henri Roukoz, Afshin Farzaneh-Far, Jeremy Markowitz, Prabhjot S Nijjar, Maneesh Bhargava and 3 more

Open access · greenAbstract read
In one paragraph

Article in JACC. Cardiovascular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Cardiac Sarcoidosis: A Comprehensive Clinical Review.Reviews in cardiovascular medicine · 2024
    Review
  17. Diagnostic testing in cardiac sarcoidosis: what comes first?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Pratik S VelangiCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Ko-Hsuan Amy ChenCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Felipe KazmirczakCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Osama OkashaCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Lisa von WaldCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Henri RoukozCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Afshin Farzaneh-FarSection of Cardiology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Jeremy MarkowitzCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Prabhjot S NijjarCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Maneesh BhargavaDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
David PerlmanDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Mehmet AkçakayaDepartment of Electrical and Computer Engineering, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota.
Chetan ShenoyCardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: cshenoy@umn.edu.
University of Minnesota Medical Center · USUniversity of Illinois Chicago · USUniversity of Minnesota · US

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related CardiotoxicityK23HL132011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2016 to 2020
$884k
Novel Accelerated Contrast-Enhanced High Resolution Coronary MRIR00HL111410 · NHLBI · UNIVERSITY OF MINNESOTA · PI AKCAKAYA, MEHMET · 2015 to 2017
$746k
NCATS NIH HHS KL2 TR000113NCATS NIH HHS UL1 TR000114NHLBI NIH HHS K23 HL132011NHLBI NIH HHS R00 HL111410
6 · The paper itself

Abstract

objectivesThis study aimed to determine the prevalence on cardiac magnetic resonance (CMR) of right ventricular (RV) systolic dysfunction and RV late gadolinium enhancement (LGE), their determinants, and their influences on long-term adverse outcomes in patients with sarcoidosis.

backgroundIn patients with sarcoidosis, RV abnormalities have been described on many imaging modalities. On CMR, RV abnormalities include RV systolic dysfunction quantified as an abnormal right ventricular ejection fraction (RVEF), and RV LGE.

methodsConsecutive patients with biopsy-proven sarcoidosis who underwent CMR for suspected cardiac involvement were studied. They were followed for 2 endpoints: all-cause death, and a composite arrhythmic endpoint of sudden cardiac death or significant ventricular arrhythmia.

resultsAmong 290 patients, RV systolic dysfunction (RVEF <40% in men and <45% in women) and RV LGE were present in 35 (12.1%) and 16 (5.5%), respectively. The median follow-up time was 3.2 years (interquartile range [IQR]: 1.6 to 5.7 years) for all-cause death and 3.0 years (IQR: 1.4 to 5.5 years) for the arrhythmic endpoint. On Cox proportional hazards regression multivariable analyses, only RVEF was independently associated with all-cause death (hazard ratio [HR]: 1.05 for every 1% decrease; 95% confidence interval [CI]: 1.01 to 1.09; p = 0.022) after adjustment for left ventricular EF, left ventricular LGE extent, and the presence of RV LGE. RVEF was not associated with the arrhythmic endpoint (HR: 1.01; 95% CI: 0.96 to 1.06; p = 0.67). Conversely, RV LGE was not associated with all-cause death (HR: 2.78; 95% CI: 0.36 to 21.66; p = 0.33), while it was independently associated with the arrhythmic endpoint (HR: 5.43; 95% CI: 1.25 to 23.47; p = 0.024).

conclusionsIn this study of patients with sarcoidosis, RV systolic dysfunction and RV LGE had distinct prognostic associations; RV systolic dysfunction but not RV LGE was independently associated with all-cause death, whereas RV LGE but not RV systolic dysfunction was independently associated with sudden cardiac death or significant ventricular arrhythmia. These findings may indicate distinct implications for the management of RV abnormalities in sarcoidosis.

Indexed as

Magnetic Resonance ImagingStroke VolumeVentricular Function, RightAdultAgedArrhythmias, CardiacDeath, Sudden, CardiacFemaleHeart VentriclesHumansMaleMiddle AgedPredictive Value of TestsPrevalencePrognosisRetrospective Studiescardiovascular magnetic resonancelate gadolinium enhancementoutcomesright ventriclesarcoidosissystolic dysfunction

Identifiers

PMID31954639
PMCPMC9303493
OpenAlexW3000640519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.